Jaguar Health, Inc. ( JAGX ) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group PLC.

The Details:

The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called “chemo mouth.” 

“We are very happy to have executed the in-license agreement for Gelclair – and thus to have initiated Jaguar’s commercial footprint in our core focus area of cancer supportive care,” said Lisa Conte, Jaguar’s president and CEO.

Jaguar Health ( JAGX ) shares are moving on heavy trading volume following the announcement with more than 240 million shares already traded in the session. According to data from Benzinga Pro, the stock’s 100-day average volume is 46.306 million shares.

Related News: What’s Going On With Rivian Automotive Stock?

Should I Sell My JAGX Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of Jaguar Health ( JAGX ) have decreased by 68.97% in the past year. An investor who bought shares of Jaguar Health ( JAGX ) at the beginning of the year would make a profit of $0.04 per share if they sold it today. The stock has risen 172.33% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital gain of $0.05.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health ( JAGX ) stock currently has an RSI of 70.7, indicating overbought conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

JAGX Price Action: According to Benzinga Pro, Jaguar Health ( JAGX ) shares are up 49.5% at 18 cents at the time of publication Tuesday.

Image from Shutterstock